|
⚲
|
| Keyboard |
| Vivo Capital LLC
✚
|
|
|---|---|
| CRD # | 159868 |
| SEC # | 801-79829 |
| CIK # | 0000167471, 0001674712 |
| AUM | 6,095.6 M (2026-03-31) |
| Employees | 62 (52% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 650-688-0818 |
| Address | 192 Lytton Avenue Palo Alto, CA 94301 |
| Source | [IAPD] [EDGAR] [Website] [Twitter] [LinkedIn] [Facebook] |
| Total AUM ($B) |
|---|
| In the News | |
|---|---|
| Fri, 31 Jul 2026 | Bright Minds Biosciences Inc. $DRUG Shares Bought by Vivo Capital LLC — MarketBeat |
| Fri, 31 Jul 2026 | Abivax SA Sponsored ADR $ABVX Shares Sold by Vivo Capital LLC — MarketBeat |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Erasca Inc | 0.2 | ||
| Praxis Precision Medicines Inc | 0.1 | ||
| Trevi Therapeutics Inc | 0.1 | ||
| DBV Technologies Sa | 0.1 | ||
| Olivia Ventures Inc | 0.1 | ||
| BCTG Acquisition Corp | 0.0 | ||
| Big Cypress Acquisition Corp | 0.0 | ||
| Corvus Pharmaceuticals Inc | 0.0 | ||
| Bright Minds Biosciences Inc | 0.0 | ||
| Magenta Therapeutics Inc | 0.0 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Vivo Arrace Fund LP | [2025-03-31] | 321.3 M | |
| Filed 2024-07-08 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| Other | Vivo Asia Spring Limited | 2025-03-31 | 10.0 M | |
| PE | Vivo Capital Fund X LP | [2024-03-28] | 717.0 M | 755.1 M |
| Filed 2026-01-20 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $100,000 · Revenue Decline to Disclose | ||||
| PE | Vivo Co-Invest C LP | [2024-03-28] | 150.0 M | |
| Filed 2023-10-27 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| Other | Vivo Asia Opportunity Fund Holdings LP | [2023-03-31] | 139.2 M | |
| Filed 2021-12-16 (D) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| SA | Vivo Co-Invest S LP | [2023-03-31] | 49.8 M | |
| Filed 2022-04-13 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Vivo Innovation Fund II Holdings LP | [2023-03-31] | 180.0 M | 341.0 M |
| Filed 2022-03-18 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| Other | Vivo Opportunity Fund Holdings LP | [2023-03-31] | 1,998.9 M | |
| Filed 2021-12-16 (D) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | Vivo Asia Opportunity Fund LP | [2022-03-31] | 148.5 M | 105.4 M |
| Filed 2025-10-10 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| VC | Vivo Innovation Fund II LP | [2021-03-31] | 180.0 M | 209.0 M |
| Filed 2022-03-18 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 16 | 6.1 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 16 | 6.1 |
| By Discretionary | ||
| Discretionary | 16 | 6.1 |
| Non-Discretionary | 0 | 0.0 |
| Total | 16 | 6.1 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.4 | |
| United States Persons | 5.7 | |
| Total | 16 | 6.1 |
| Limited Partners | 2011 - 2026 |
|---|---|
| California State Teachers' Retirement System |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Chen Yu | Director | 24 | 3 | |
| Gaurav Aggarwal | Director, Executive Officer | 19 | 3 | |
| Albert Cha | Director, Executive Officer | 46 | 2 | |
| Frank Kung | Director, Executive Officer | 45 | 2 | |
| Jack Nielsen | Director | 44 | 2 | |
| Michael Chang | Director, Executive Officer | 38 | 2 | |
| Edgar Engleman | Director | 29 | 2 | |
| Mahendra Shah | Director, Executive Officer | 26 | 2 | |
| Hongbo Lu | Director | 17 | 2 | |
| David Liu | Director | 16 | 2 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001674712] | |
| 3 | [0001674712] | |
| 4 | [0001674712] | |
| SC 13D | [0001674712] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Vivo Capital LLC | Sinovac Biotech Ltd | [2018-07-11] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Private Equity |
| LEI | 25490014X9LPHXWXCC91 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Crinetics Pharmaceuticals Inc CRNX
Common Stock
|
2018-07-20 | Conversion | 353,590 | ||
|
Crinetics Pharmaceuticals Inc CRNX
Common Stock
|
2018-07-20 | Conversion | 2,560,613 | ||
|
Crinetics Pharmaceuticals Inc CRNX
Common Stock
|
2018-07-20 | Buy | 153,180 | $20.73 | 3,175,421 |
|
Crinetics Pharmaceuticals Inc CRNX
Common Stock
|
2018-07-20 | Buy | 141,177 | $17.00 | 2,400,009 |
|
Crinetics Pharmaceuticals Inc CRNX
Common Stock
|
2018-07-20 | Buy | 7,137 | $17.00 | 121,329 |
|
Crinetics Pharmaceuticals Inc CRNX
Common Stock
|
2018-07-20 | Buy | 51,686 | $17.00 | 878,662 |
|
Crinetics Pharmaceuticals Inc CRNX
Common Stock
|
2018-07-20 | Conversion | 413,040 | ||
|
Crinetics Pharmaceuticals Inc CRNX
Common Stock
|
2018-07-20 | Conversion | 57,035 | ||
|
Crinetics Pharmaceuticals Inc CRNX
Series A Preferred Stock · derivative
|
2018-07-20 | Conversion | 1,163,311 | ||
|
Crinetics Pharmaceuticals Inc CRNX
Series B Preferred Stock · derivative
|
2018-07-20 | Conversion | 1,358,903 | ||
|
Crinetics Pharmaceuticals Inc CRNX
Series B Preferred Stock · derivative
|
2018-07-20 | Conversion | 187,648 | ||
|
Crinetics Pharmaceuticals Inc CRNX
Series A Preferred Stock · derivative
|
2018-07-20 | Conversion | 8,424,416 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Riverwood Capital Management LP
✚
|
CA | 6,166.0 M |
|
Tikehau Capital North America LLC
✚
|
NY | 6,163.9 M |
|
A Fin Management LLC
✚
|
FL | 6,160.3 M |
|
Freeman Spogli Management Co LP
✚
|
CA | 6,160.3 M |
|
Lotus Infrastructure Partners LP
✚
|
CT | 6,155.6 M |
|
Primary Wave IP Investment Management LLC
✚
|
NY | 6,136.2 M |
|
Vision Ridge Partners LLC
✚
|
CO | 6,109.8 M |
|
Warren Equity Partners Manager LP
✚
|
FL | 6,088.1 M |
|
Haveli Investment Management LLC
✚
|
TX | 6,031.1 M |
|
Trivest Investment Advisors LLC
✚
|
FL | 6,011.2 M |